Cambrex acquires Avista for $252m, becomes integrated CDMO

By Maggie Lynch

- Last updated on GMT

(Image: Getty/djiledesign)
(Image: Getty/djiledesign)

Related tags CDMO Mergers and acquisitions Early stage Health care Drug development API Small molecule

Cambrex is set to acquire Avista and enter the market of early stage small molecule development and testing.

Avista, a contract development and manufacturing organization (CDMO), will continue to offer a broad range of services ranging from drug product development and current good manufacturing process (cGMP) manufacturing to stand-alone analytical, microbiology testing and solid-state sciences​. 

Through this acquisition, Cambrex – which manufactures small molecule and generic active pharmaceutical ingredients​ (APIs) and finished dosage forms – will become an integrated small molecule CDMO providing services across the entire drug lifecycle.

The $252m (€221.6) deal is expected to be funded with a combination of cash and borrowings under Cambrex’s existing revolving credit facility.

Avista has four facilities, three located throughout the US and one in Edinburg, Scotland. Upon completion of the transaction, Avista is expected to generate roughly $65m in annual revenue. Avista’s 300 employees will join Cambrex​’s 1,700 employees across the US and Europe.

Avista is a portfolio company​ of Ampersand Capital Partners, a health care private equity firm. Recently, Neomed-Labs and Pacific Biomarkers ​were merged following an acquisition made by Ampersand partners.

Completion of the transaction is expected to occur during the fourth quarter of 2018.

Related news

Show more

Related products

show more

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Related suppliers

Follow us


View more